Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2023-12-22 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It announces the FDA approval of a drug (Wainua) and provides detailed information about the drug, clinical trial results, and company background. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory announcement about a significant event (FDA approval) and includes detailed information but does not contain financial statements or management analysis typical of financial reports. Form 6-K filings are generally considered Regulatory Filings (RNS) as they provide material information to the market but do not fit into other specific categories like earnings releases or annual reports. The document length is over 13,000 characters, so it is not a brief announcement but a full regulatory disclosure. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-12-22 English
Wainua (eplontersen) granted first US FDA approval
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 7566X' and concludes with information about RNS, the news service of the London Stock Exchange, and an 'END' marker followed by a ticker/identifier. This structure is characteristic of a regulatory news service announcement. The content details a significant corporate event: the US FDA approval of a drug (Wainua/eplontersen) by AstraZeneca. This type of material announcement, which is not a full financial report (like 10-K or IR) but a material corporate update disseminated via an official channel, fits best under the general 'Regulatory Filings' category (RNS) or potentially an 'Earnings Release' (ER) if it were financial results, but here it is a product/regulatory milestone announcement. Since RNS is the designated fallback for general regulatory announcements not covered by other specific codes (like DIV, CAP, MANG), and the document explicitly identifies itself as an RNS release, 'RNS' is the most appropriate classification.
2023-12-22 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 100% confidence The document is a Form 6-K filing by AstraZeneca PLC, reporting a transaction by a person discharging managerial responsibilities (PDMR), specifically a Non-Executive Director purchasing shares. The content focuses on insider shareholding disclosure, detailing the purchase of ordinary shares by a director. It is not an annual or interim report, audit report, earnings release, or any other financial or governance report. It is a notification of a director's dealing in company shares, which fits the category of Director's Dealing filings. The document length is 4152 characters, which is consistent with a detailed insider transaction report. Therefore, the appropriate classification is Director's Dealing (DIRS).
2023-12-14 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification disseminated via RNS (RNS Number: 7145W) on December 14, 2023. The content explicitly details a 'Transaction by Person Discharging Managerial Responsibilities' (Anna Manz, Non-Executive Director) involving the purchase of the company's ordinary shares. This directly corresponds to the definition of Director's Dealing (insider trades). Therefore, the appropriate filing code is DIRS.
2023-12-14 English
FORM 6-K
M&A Activity Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content primarily details AstraZeneca's announcement of its definitive agreement to acquire Icosavax, including transaction details, financial considerations, and forward-looking statements. The document includes information about the tender offer, merger conditions, and regulatory filings related to the acquisition. This type of document is an announcement of a merger and acquisition transaction rather than the full merger filing itself (such as a Schedule 14D-9 or Schedule TO). It is not a full annual or interim report, earnings release, or other financial report. Given the detailed description of the acquisition and tender offer, the document fits best under the category of M&A Activity (TAR). The length and detail confirm it is not a brief announcement or a regulatory filing fallback. Therefore, the classification is M&A Activity (TAR) with high confidence.
2023-12-12 English
ASTRAZENECA TO ACQUIRE ICOSAVAX
M&A Activity Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer submitted to the SEC. The content details AstraZeneca's definitive agreement to acquire Icosavax, including transaction terms, strategic rationale, and forward-looking statements. It includes detailed information about the acquisition, tender offer, and regulatory filings related to the transaction. This type of document is an announcement of a merger/acquisition activity rather than a full merger proxy statement or tender offer filing itself. The document is not an annual or quarterly report, earnings release, or other financial report. It is a regulatory filing reporting material corporate transaction information. Therefore, the most appropriate classification is M&A Activity (TAR).
2023-12-12 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.